复发/晚期乳腺癌区域淋巴结的PET/CT分布图谱及与现有勾画图谱的比较
本研究纳入154例复发/晚期乳腺癌患者,基于18F-FDG PET/CT定位348个受累淋巴结区域,评估RADCOMP、RUIJIN、RTOG和ESTRO四种指南CTV的覆盖情况。RADCOMP(306/348)和RUIJIN(291/348)覆盖率高于RTOG(205/348)和ESTRO(202/348)(均P<0.001),SC-L和IMN为主要遗漏区域。
要点
- 复发腋窝淋巴结主要位于腋静脉的头侧和腹侧。
- RADCOMP和RUIJIN图谱对区域淋巴结的覆盖率高于RTOG和ESTRO(P<0.001)。
- SC-L和IMN是各指南的主要遗漏区域,临床阳性SC患者CTV建议延伸至舌骨水平。
核心结论
- 现有指南能有效覆盖术后乳腺癌患者的大部分区域淋巴结,但SC-L和IMN是主要遗漏区域;复发腋窝淋巴结多位于腋静脉头侧和腹侧;临床阳性SC患者的CTV推荐延伸至舌骨水平;CTV应根据个体复发风险调整。
研究设计与样本
- 单中心研究,纳入2018年1月至2020年6月期间接受PET/CT检查的154例复发/晚期乳腺癌患者,记录腋窝淋巴结I-III区、Rotter淋巴结、内侧锁骨上、外侧锁骨上及内乳淋巴结受累情况,评估不同图谱CTV覆盖及野外位置。
关键影像表现/征象
- 共识别348个含病变淋巴结区域:ALN-I 109个、ALN-II 46个、ALN-III 36个、RN 17个、SC-M 68个、SC-L 36个、IMN 36个。
- 复发腋窝淋巴结主要位于腋静脉头侧和腹侧。
- 76例SC阳性患者中33例同侧颈部淋巴结同时受累。
诊断标准与关键数值
- RADCOMP图谱覆盖306/348个区域,RUIJIN覆盖291/348个,均高于RTOG的205/348和ESTRO的202/348(分别P<0.001)。
- 在原发非转移和复发患者中,RTOG指南的主要遗漏位于SC-L(7/7,17/17)和IMN(7/10,15/19),ESTRO指南主要遗漏位于SC-L(7/7,17/17)(分别P<0.001)。
- 在复发患者中,ESTRO指南的另一主要遗漏区域为SC-M(22/31)(P<0.001)。
临床应用与阅片要点
- 作者建议临床阳性SC患者的CTV应延伸至舌骨水平。
- 作者建议CTV应根据个体复发风险进行调整。
- 作者指出复发患者的高位腋窝包括锁骨下淋巴结和腋静脉上方的Rotter淋巴结,以及阳性SC患者环状软骨与舌骨之间的区域应仔细勾画。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To localize the distribution of regional nodes in recurrent/advanced breast cancer patients based on 18-fludeoxyglucose (FDG) positron emission tomography/CT (PET/CT) images and validate the coverage of clinical target volumes (CTVs) for regional nodes with current contouring guidelines.
METHODS: We enrolled 154 recurrent/advanced breast cancer patients with FDG-avid regional nodes who underwent PET/CT between January 2018 and June 2020. Involvement of lymph node regions including axillary lymph node level I-III (ALN-I, ALN-II, ALN-III), Rotter's nodes (RN), medial supraclavicular (SC-M), lateral supraclavicular (SC-L) and internal mammary nodes (IMN) was recorded respectively. Coverage of the CTVs in different atlases and the locations of out-of-field were evaluated.
RESULTS: A total of 348 lymph node regions containing disease were identified, including ALN-I 109, ALN-II 46, ALN-III 36, RN 17, SC-M 68, SC-L 36 and IMN 36. Recurrent ALNs mainly located cranially and ventrally to the axillary vein (AV). Ipsilateral cervical nodes were simultaneously affected in 33/76 SC positive patients. RADCOMP (306/348) and RUIJIN (291/348) guidelines had higher coverage compared with RTOG (205/348) and ESTRO (202/348) guidelines (p < 0.001, respectively). In primary non-metastastic and recurrent patients, major missings located in SC-L (7/7, 17/17) and IMN (7/10, 15/19) for RTOG guideline while SC-L (7/7, 17/17) for ESTRO guideline (p < 0.001, respectively). Among recurrent patients, SC-M (22/31) was another major missing area for ESTRO guideline (p < 0.001).
CONCLUSION: The current guidelines effectively cover most regional nodes in postoperative breast cancer patients. SC-L and IMN were the major missing regions. Recurrent ALNs were most often seen in cranial and ventral to the AV. The CTV of patients with clinically positive SC was recommended to extend up to the hyoid level. The CTVs should be adjusted based on risks of recurrence individually.
ADVANCES IN KNOWLEDGE: The difference of regional nodes delineation between current guidelines mainly located in SC and IMN regions. High axilla including subclavicular nodes and the RN above AV for recurrent patients and the region between cricoid and hyoid for positive SC patients should be meticulously contoured.
引用
- Zhang, Cao, Chen, et al. Mapping of PET/CT-based regional nodes distribution of recurrent/advanced breast cancer and comparison with current delineation atlas. Br J Radiol. 2022. PMID: 35731844. doi:10.1259/bjr.20220382
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。